What is Alomide used for?

Alomide is indicated for Vernal Keratitis, Vernal conjunctivitis, Vernal keratoconjunctivitis.

Alomide is developed by Novartis.

What development phase is Alomide in?

Alomide is FDA-approved (marketed).

What is the generic name of Alomide?

LODOXAMIDE is the generic (nonproprietary) name of Alomide.

Last reviewed 2026-04-20 · How we verify

Alomide (LODOXAMIDE)

Novartis · FDA-approved approved Small molecule Quality 30/100

Alomide (LODOXAMIDE) is a small molecule mast cell stabilizer that targets G-protein coupled receptor 35. It was originally developed by ALCON and is currently owned by Novartis. Alomide is FDA-approved for the treatment of Vernal Keratitis, Vernal conjunctivitis, and Vernal keratoconjunctivitis. The drug is off-patent, meaning it is no longer protected by patents, and there are no generic manufacturers. As a result, its commercial status is uncertain.

At a glance

Generic name	LODOXAMIDE
Sponsor	Novartis
Drug class	Mast Cell Stabilizer
Target	G-protein coupled receptor 35
Modality	Small molecule
Therapeutic area	Rare Disease
Phase	FDA-approved
First approval	1993

Approved indications

Vernal Keratitis
Vernal conjunctivitis
Vernal keratoconjunctivitis

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Alomide CI brief — competitive landscape report
Alomide updates RSS · CI watch RSS
Novartis portfolio CI